Webb6 mars 2024 · Find the latest Earnings Report Date for Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) at Nasdaq.com. WebbFör 1 dag sedan · Toute l'actualité sur REATA PHARMACEUTICALS, INC. Plus d'actualités Recommandations des analystes sur REATA PHARMACEUTICALS, INC. Plus de recommandations Données financières Plus de...
Q1 2024 Earnings Estimate for Reata Pharmaceuticals, Inc.
Webb11 apr. 2024 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Reata Pharmaceuticals stock is Moderate Buy based on the current 1 hold … Webb28 feb. 2024 · PLANO, Texas, February 28, 2024 -- ( BUSINESS WIRE )-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a … roof-all
RETA Reata Pharmaceuticals Inc. - InvestorsObserver
Webb14 apr. 2024 · Reata Pharmaceuticals Inc is around the top of the Biotechnology industry according to InvestorsObserver.RETA received an overall rating of 67, which means that … WebbTrend Table for RETA - Reata Pharmaceuticals, Inc. - Class A. RETA Chart by TradingView Watchlist Portfolio. Current Trend Strength: Strong Date Grade ADX Long Term Intermediate Term Short Term % Chg Jan 12: C: Weak or Absent: Up : Up : Up : 156.11%: Webb12 apr. 2024 · The stock of Larimar Therapeutics has risen 37.4% in the past year against a decrease of 16.6% for the industry. Loss estimates for 2024 have narrowed from $2.07 per share to $1.08 per share over ... roof-beam